Menu

Top Stories

Published on Thursday, May 28, 2015

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Alpha-1 Foundation on Thursday congratulated the investigators and sponsor of the RAPID Trial, demonstrating the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency, on the publication of the trial in The Lancet, one of the world’s oldest and most prestigious medical journals.

The Lancet article was posted online this week.

When the results were first announced at the international conference of the American Thoracic Society (ATS) in 2013, lead author Kenneth Chapman, MD, director of the Asthma and Airway Centre of the University Health Network in Toronto, Canada, called the trial “the most rigorous evidence to date that augmentation therapy slows the progression of emphysema in patients with Alpha-1 Antitrypsin Deficiency. The effect of A1-PI seen in this trial was both clinically and statistically significant, finally confirming its benefit in preventing the loss of lung tissue in patients with this potentially debilitating disease.”

The Alpha-1 Foundation hailed the trial results and The Lancet publication. "We congratulate CSL on this landmark clinical trial, which provides the strongest evidence yet that augmentation therapy preserves the lung tissue of individuals with Alpha-1-related lung disease," said John Walsh, Foundation president and CEO. "We hope these results will support Alpha-1 communities around the world in their efforts to win access to therapy.”

Walsh said, “The Foundation has communicated its support for acceptance of the RAPID data as proof of efficacy of augmentation therapy to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (the European equivalent of the FDA), and has continued a dialogue with both agencies to urge acceptance of these findings.”

CSL Behring sponsored the trial, which randomly assigned 180 Alpha-1 patients to receive either the augmentation product Zemaira or a placebo for a two-year period, followed by a two year of open-label extension study in which all subjects were offered augmentation therapy. “We applaud CSL for its commitment of time and effort to conduct this multinational, multi-year study, and we’re delighted that The Lancet has published the RAPID Trial results,” said Walsh. 

The Lancet article says that an interim analysis of data from the two-year extension trial suggest that early treatment with augmentation therapy shows persistent efficacy in patients with Alpha-1 and emphysema. In addition, when patients who had been receiving a placebo in the original two-year trial switched to treatment with augmentation therapy, their lung density decline (which was more rapid than the treated group in the main study) slowed to the same rate as the treatment group. “These findings should encourage early introduction of augmentation therapy [in patients with emphysema due to Alpha-1] and should stimulate further research into optimum dosing,” says the Lancet article.

Robert Sandhaus, MD, PhD, clinical director of the Alpha-1 Foundation and medical director of AlphaNet, was a co-author of the Lancet article.

The RAPID Trial is the first well-powered randomized, placebo-controlled trial to use CT scan lung density as the primary outcome measure. CT scans are currently considered the most sensitive measure of emphysema detection. The trial was conducted at 28 sites in the United States, Europe, Canada, Australia and Russia.

The multi-center, multi-national trial randomized patients with homozygous Alpha-1 (ZZ) to receive either alpha-1 antitrypsin augmentation therapy intravenously at 60 mg/kg weekly or a placebo over two years. CT scan lung density was measured at baseline, three months, one and two years. Secondary endpoints included spirometry, changes in exercise capacity and the rate of pulmonary exacerbations over two years.

The annual rate of lung density loss was significantly less in augmentation-treated patients (-1.45 +/- 0.24 units vs. -2.19 +/-0.25 units; p = 0.017, one-sided). Secondary outcome variables and adverse events were not significantly different between groups, according to the article. There was one death in the augmentation therapy group and three in the placebo group.

Attached is the full article published in The Lancet, with an accompanying editorial by Ronald Crystal, MD, Department of Genetic Medicine, Weill Cornell Medical College.

Photo at top: Ken Chapman, MD. Below: John Walsh, left, and Robert Sandhaus, MD.


Print

Recruitment begins for gene therapy clinical trial for Alpha-1 Antitrypsin Deficiency

Tuesday, December 5, 2017
Enrollment for a trial for a new treatment for Alpha–1 related lung disease begins today. Adverum Biotechnologies, in partnership with the Alpha–1 Foundation will be recruiting patients, as well as healthy ZZ and Znull...
Divider

Your helping hand has an impact for Alphas worldwide

Friday, December 1, 2017
When you donate to the Alpha–1 Foundation, you are helping Alphas everywhere by providing support services to newly diagnosed adults and children, giving access to education to both Alphas and medical professionals, allowing for family...
Divider

UK company acquires license for a potential pill-based Alpha–1 lung therapy

Wednesday, November 1, 2017
Mereo BioPharma Group, a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, announced that it has reached an agreement with AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an...
Divider

Uncertainty added to health insurance markets

Friday, October 13, 2017
It has been an eventful 24 hours in Washington as President Trump made a number of announcements related to health insurance policy.  First, he signed an executive order that seeks to increase competition by facilitating access to association...
Divider

Celebrating plasma donors worldwide

Wednesday, October 11, 2017
International Plasma Awareness Week (IPAW) brings awareness to the importance of plasma donors worldwide. “During PPTA’s International Plasma Awareness Week, we want to thank all the donors that make life sustaining Alpha–1...
Divider

Medicare says 2018 to offer more health coverage choices and decreased premiums

Friday, September 29, 2017
Today, the Centers for Medicare & Medicaid Services (CMS) announced that people with Medicare will have more choices and options for their Medicare coverage in 2018. As CMS releases the benefit and premium information for Medicare health and...
Divider

Record-breaking year for Team Alpha-1 at Escape to the Cape

Friday, September 29, 2017
As summer wanes and fall begins, Team Alpha–1 is decompressing from another successful Autumn Escape Bike Trek. This year has seen many firsts over our 23-year history of participating in this event with the American Lung Association of the...
Divider

Bob Campbell passes away, Foundation Communications Director, former AlphaNet Coordinator

Friday, July 28, 2017
Our dear friend and colleague, Bob Campbell passed Thursday evening with his wife Elizabeth by his side. Campbell began his Alpha-1 journey when he was diagnosed by his allergist. In 2002, he took the leap and became an AlphaNet...
Divider

Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin Treatment

Friday, July 21, 2017
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its...
Divider

Foundation president and CEO urges Alphas to find their place in the Alpha-1 Community

Thursday, June 29, 2017
CHICAGO, Illinois – Henry Moehring, president and CEO of the Alpha–1 Foundation, presided over the 26th and largest National Education Conference of the Alpha–1 community since its inception, he said in his Foundation update...
Divider

Alpha-1 Foundation Accepting Proposals for the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency

Wednesday, June 28, 2017
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. This award is named after John W. Walsh, who dedicated his life’s work to finding...
Divider

Barbara Pusey honored in memoriam at Alpha–1 awards and recognition night

Monday, June 26, 2017
Barbara Pusey, who was the first AlphaNet Coordinator for the augmentation therapy marketed in the United States as Zemaira and was a major influence in building the AlphaNet Zemaira program into what it is today, was recognized posthumously, with...
Divider
12345678

Article Search

Enter keywords in text box and click Search button for results.